Skip to Content

News & Events

Press Releases

Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryMay 6, 2008	Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences CAMBRIDGE, Mass., May 06, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentations at the Bank of America 2008 Health Care Webcasts	View HTML Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences 6.8 KB
Toggle SummaryMay 15, 2008	Stockholders of Vertex Pharmaceuticals Approve Proxy Proposals at Annual Meeting CAMBRIDGE, Mass., May 15, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results of the voting at its 2008 Annual Meeting of Stockholders. At the meeting, stockholders approved the amendment to Vertex's Articles of Organization increasing the number of General Business	View HTML Stockholders of Vertex Pharmaceuticals Approve Proxy Proposals at Annual Meeting 7.7 KB
Toggle SummaryMay 16, 2008	Vertex Pharmaceuticals Announces Webcast of its Presentation at the 2008 Citi Investment Research Global Healthcare Conference CAMBRIDGE, Mass., May 16, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 2008 Citi Investment Research Global Healthcare Conference on Wednesday, May 21, 2008 at 1:00 p.m. EDT. Webcasts	View HTML Vertex Pharmaceuticals Announces Webcast of its Presentation at the 2008 Citi Investment Research Global Healthcare Conference 7.8 KB
Toggle SummaryJun 3, 2008	Vertex Pharmaceuticals Sells HIV Product Royalty Stream for $160 Million CAMBRIDGE, Mass., Jun 03, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has sold its rights to future royalties in Lexiva(R) and Agenerase(R) under its 1993 license agreement with GlaxoSmithKline plc (GSK) in the field of HIV protease inhibitors General Business	View HTML Vertex Pharmaceuticals Sells HIV Product Royalty Stream for $160 Million 10.3 KB
Toggle SummaryJun 6, 2008	Vertex Pharmaceuticals Announces Webcast of its Presentation at the Goldman Sachs 29th Annual Global Healthcare Conference CAMBRIDGE, Mass., Jun 06, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the Goldman Sachs 29th Annual Global Healthcare Conference on Wednesday, June 11, 2008 at 4:00 p.m. PDT (7:00 p.m. EDT). Webcasts	View HTML Vertex Pharmaceuticals Announces Webcast of its Presentation at the Goldman Sachs 29th Annual Global Healthcare Conference 7.8 KB
Toggle SummaryJun 9, 2008	Vertex Reports 52% SVR 12 Rate for a 24-week Telaprevir-based Regimen in Genotype 1 Hepatitis C Patients Who Failed Prior Treatment -- 73% of prior relapsers achieved SVR12 with 24-week<br> telaprevir-based treatment<br><br> -- 41% of prior non-responders achieved SVR12 with 24-week<br> telaprevir-based regimen HCV	View HTML Vertex Reports 52% SVR 12 Rate for a 24-week Telaprevir-based Regimen in Genotype 1 Hepatitis C Patients Who Failed Prior Treatment 22.9 KB
Toggle SummaryJun 17, 2008	Vertex Establishes Early-Stage Huntington's Disease Research Collaboration with CHDI Foundation, Inc. Vertex Establishes Early-Stage Huntington's Disease Research Collaboration with CHDI Foundation, Inc. -Vertex to receive up to $4 million in funding for Huntington's disease research- -Novel venture philanthropy model used in Vertex's Cystic Fibrosis R&D efforts to support new Huntington's disease General Business	View HTML Vertex Establishes Early-Stage Huntington's Disease Research Collaboration with CHDI Foundation, Inc. 13.5 KB
Toggle SummaryJun 18, 2008	Vertex Pharmaceuticals Announces the Appointment of Freda C. Lewis-Hall, M.D., as Executive Vice President, Medicines Development CAMBRIDGE, Mass., Jun 18, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced the appointment of Freda C. Lewis-Hall, M.D. as Executive Vice President, Medicines Development. Dr. Lewis-Hall joins Vertex from Bristol-Myers Squibb, Incorporated, and has General Business	View HTML Vertex Pharmaceuticals Announces the Appointment of Freda C. Lewis-Hall, M.D., as Executive Vice President, Medicines Development 11.5 KB
Toggle SummaryJul 17, 2008	Vertex Pharmaceuticals Announces the Date of its Second Quarter 2008 Financial Results Conference Call and Webcast CAMBRIDGE, Mass., Jul 17, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its second quarter 2008 financial results on Thursday, July 31, 2008 after the financial markets close. The Company will host a conference call at 5:00 p.m. EDT. Webcasts	View HTML Vertex Pharmaceuticals Announces the Date of its Second Quarter 2008 Financial Results Conference Call and Webcast 7.8 KB
Toggle SummaryJul 31, 2008	Vertex Pharmaceuticals Highlights Telaprevir Progress and Reports Second Quarter 2008 Results -- Treatment-failure data and treatment-naive data strengthen<br> telaprevir's potential profile and highlight broad opportunity<br> in treatment of chronic hepatitis C virus (HCV) infection<br><br> -- VX-770, for cystic fibrosis (CF), completes enrollment for<br> 28-day Phase 2a study; 2009 targeted for initiation of<br> registration studies, pending 28-day study results Webcasts	View HTML Vertex Pharmaceuticals Highlights Telaprevir Progress and Reports Second Quarter 2008 Results 42.3 KB